Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pruritus
100%
Immune-Related Adverse Events
85%
Immune Checkpoint Inhibitor
85%
Malignant Neoplasm
85%
Acrylic Acid Derivative
85%
Skin Allergy
85%
Cosmetics
85%
Neurokinin 1 Receptor Antagonist
85%
Systematic Review
85%
Meta-Analysis
85%
Acrylic Acid
64%
Immunotherapy
57%
Randomized Controlled Trial
47%
Placebo
28%
Nail Dystrophy
21%
Cosmetic
21%
Patch Test
21%
Pulpitis
21%
Hand Eczema
21%
Contact Allergen
21%
Sensitization
21%
Aprepitant
19%
Serlopitant
19%
Neurokinin 1 Receptor
19%
Dermatological Disease
19%
Maculopapular Rash
14%
Adverse Event
14%
Log Rank Test
14%
Survival Time
14%
Cancer Types
14%
Overall Survival
14%
Survival Rate
14%
Retrospective Cohort Study
14%
Monotherapy
14%
Patient Referral
14%
Oncology
14%
Molecularly Targeted Therapy
14%
Pembrolizumab
14%
Treatment Duration
9%
Diseases
9%
Clinician
9%
Therapy Effect
9%
Subgroup Analysis
9%
Cell Signaling Pathway
9%
Substance P
9%
Antipruritic
9%
Neuroscience
Immunotherapy
85%
Neurokinin 1 Receptor
85%
Meta-Analysis
85%
Receptor Antagonist
85%
Systematic Review
85%
Randomized Controlled Trial
42%
Placebo
25%
Lambrolizumab
21%
Aprepitant
17%
Substance P
8%
Antipruritic
8%
Pharmacology, Toxicology and Pharmaceutical Science
Neurokinin 1 Receptor Antagonist
85%
Pruritus
85%
Randomized Controlled Trial
47%
Placebo
28%
Serlopitant
19%
Aprepitant
19%
Neurokinin 1 Receptor
19%
Diseases
9%
Antipruritic Agent
9%
Therapeutic Effect
9%
Substance P
9%